Betaseron Related Published Studies
Well-designed clinical trials related to Betaseron (Interferon Beta-1B)
Interferon beta-1b reduces black holes in a randomised trial of clinically
isolated syndrome. [2014]
Cognitive dysfunction in patients with multiple sclerosis treated with different
types of interferon beta: a randomized clinical trial. [2014]
Interferon beta for secondary progressive multiple sclerosis. [2012]
Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. [2011.08.30]
Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. [2011.04.05]
[Interferon beta for multiple sclerosis. How much is good enough?]. [2010.12]
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. [2010.06.08]
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. [2010.04]
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of
relapsing multiple sclerosis. [2010]
SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. [2009.12.14]
Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study. [2009.12]
New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. [2009.12]
A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. [2009.10]
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. [2009.09.29]
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. [2009.08]
Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. [2008.08.13]
Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. [2008.06.17]
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. [2008.04]
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. [2007.09]
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. [2007.08.04]
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. [2006.10.10]
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. [2006.04.11]
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. [2006.02]
Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis. [2006.01]
Response to interferon beta-1a treatment in African American multiple sclerosis patients. [2005.11]
Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. [2005.05]
Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis. [2005.05]
Interferon beta-1b treatment does not induce autoantibodies. [2005.03.22]
Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. [2005.02.22]
Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. [2004.12]
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. [2004.11.23]
Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. [2004.06]
Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta. [2003.08]
The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. [2003.03.11]
Interferon beta-1a in primary progressive multiple sclerosis. [2003.02.15]
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. [2003.01.14]
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). [2002.04.27]
A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). [2002.04.01]
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. [2001.12.26]
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. [2001.11.27]
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. [2001.07]
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. [2001.03]
The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. [2000.06]
Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group. [2000.01.11]
Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. [1999.12]
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis] [1999.08]
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. [1999.06.10]
The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. [1999.04.12]
Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. [1999.01.15]
Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. [1998.11]
Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. [1998.10]
Interferon beta-1b: latest published results, 1995. [1996.07]
Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. [1996.06]
Betaseron: the new MS treatment. [1994.02]
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. [1993.10]
Phase II trials of interferons-alpha and -beta in advanced sarcomas. [1992.12]
Otologic effects of interferon beta serine in experimental rhinovirus colds. [1992.09]
Biological and clinical effects of interferon-beta ser at two doses. [1990.12]
Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds. [1989.10]
Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults. [1988.07]
Well-designed clinical trials possibly related to Betaseron (Interferon Beta-1B)
Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis. [2011.04]
Long-term follow-up of clinical trials of multiple sclerosis therapies. [2011.01.04]
The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study. [2010.03]
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [2009.11.10]
Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. [2009.11.03]
Serum levels of CXCL13 are elevated in active multiple sclerosis. [2009.11]
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [2009.09.30]
Adverse drug reactions after 24-month treatment with two-dosage regimens of betaferon in patients with multiple sclerosis. [2009.07]
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. [2009.06.09]
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. [2009.05.20]
Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. [2008.08]
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. [2008.08]
A clinical study of multiple sclerosis patients treated with betaferon. [2008.07]
Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis. [2008.05]
Adherence to therapy: using an evidence-based protocol. [2007.11]
Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. [2007.08]
Lack of association between antimyelin antibodies and progression to multiple sclerosis. [2007.01.25]
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. [2006.05]
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. [2003.05.13]
Randomized controlled trials to assess therapies for multiple sclerosis. [2002.04.23]
Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. [2002.01]
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. [2001.12.26]
Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. [2001.12.11]
A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. [1998.12]
Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. [1998.07]
Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS. [1998.06]
IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. [1997.06]
Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. [1995.10]
Other research related to Betaseron (Interferon Beta-1B)
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple
sclerosis. [2014]
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. [2011.12]
Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Follow-up. [2011.11]
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. [2011.09.30]
Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials. [2011.05.26]
Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. [2011.04]
Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. [2011.03.15]
Interferon-beta-1b: a review of its use in multiple sclerosis. [2011.01.01]
Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. [2011]
Therapeutic efficacy of interferon beta-1b in Japanese patients with optic-spinal multiple sclerosis. [2011]
Apolipoprotein alleles and the response to interferon-beta-1b in multiple sclerosis. [2011]
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. [2010.10]
A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. [2010.10]
|